The 10 US Biosimilar Launches That Could Drive Big Savings By 2027

 
• By Jessica Merrill

Biosimilar versions of drugs like Humira, Stelara and Eylea are among the products that could generate cumulative sales of $129bn over the next five years, according to IQVIA.

Dice going up and down
The US is expected to spend more on biosimilars and save more on healthcare costs • Source: Shutterstock

Despite continued uncertainty about how exactly the US biosimilar market will evolve, US spending on biosimilars is poised to grow substantially from 2023 to 2027, generating billions in US health care savings, according to a report on biosimilars by the IQVIA Institute for Human Data Science.

At least 10 molecules are expected to face biosimilar competition in the period from 2023 to 2027, which will drive growth of the US biosimilars market,

More from Strategy

More from Business